Oppenheimer on Nurix (NRIX): 'We think this part of the story is getting more interesting'
Oppenheimer analyst Matthew Biegler reiterated an Outperform rating and $28.00 price target on Nurix (NASDAQ: NRIX).The analyst comments "Nurix reported ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)